title: Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts.
abstract: Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.
authors.affiliation: Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
authors.forename: W D
authors.initials: WD
authors.lastname: Clouse
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: M R
authors.initials: MR
authors.lastname: Phillips
authors.forename: R D
authors.initials: RD
authors.lastname: Hurt
authors.forename: L A
authors.initials: LA
authors.lastname: Fitzpatrick
authors.forename: T P
authors.initials: TP
authors.lastname: Moyer
authors.forename: C
authors.initials: C
authors.lastname: Rowland
authors.forename: H V
authors.initials: HV
authors.lastname: Schaff
authors.forename: V M
authors.initials: VM
authors.lastname: Miller
mesh_terms: D000199:Actins / Q000378:metabolism; D000279:Administration, Cutaneous; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D001026:Coronary Artery Bypass; D003367:Cotinine / Q000097:blood; D003893:Desmin / Q000378:metabolism; D015194:Diffusion Chambers, Culture; D004285:Dogs; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D058574:Integrin-Binding Sialoprotein; D007476:Ionophores / Q000494:pharmacology; D008297:Male; D009538:Nicotine / Q000097:blood / Q000494:pharmacology*; D009566:Nitrates / Q000097:blood; D009569:Nitric Oxide / Q000494:pharmacology; D009573:Nitrites / Q000097:blood; D012501:Saphenous Vein / Q000187:drug effects* / Q000378:metabolism / Q000637:transplantation*; D012795:Sialoglycoproteins / Q000378:metabolism; D013917:Thrombin / Q000494:pharmacology; D014664:Vasodilation
chemical_list: D000199:Actins; D003893:Desmin; C546871:IBSP protein, human; D058574:Integrin-Binding Sialoprotein; D007476:Ionophores; D009566:Nitrates; D009573:Nitrites; D012795:Sialoglycoproteins; D009569:Nitric Oxide; D000001:Calcimycin; D009538:Nicotine; D013917:Thrombin; D003367:Cotinine